NCT00132925 is a Phase 3 clinical trial of Triamcinolone in Rhinitis, Allergic, Perennial, sponsored by Sanofi.

Who is sponsoring NCT00132925?

NCT00132925 is sponsored by Sanofi.

What drugs are being tested in NCT00132925?

Interventions in NCT00132925: Triamcinolone.

What condition does NCT00132925 study?

NCT00132925 studies Rhinitis, Allergic, Perennial.

Is NCT00132925 still recruiting?

NCT00132925 is currently completed. Last updated 10 January 2011.

Last reviewed 2011-01-10 · How we verify

NCT00132925

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis

Completed Phase 3 Last updated 10 January 2011

What this trial tests

Phase 3 trial testing Triamcinolone in Rhinitis, Allergic, Perennial in 460 participants. Completed in 1 February 2006.

Timeline

1 November 2003

1 February 2006

Quick facts

Lead sponsor	Sanofi
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	460
Start date	1 November 2003
Estimated completion	1 February 2006
Sites	1 location across United States

Drugs / interventions tested

Triamcinolone (TRIAMCINOLONE) — full drug profile →

Conditions studied

Rhinitis, Allergic, Perennial — all drugs for Rhinitis, Allergic, Perennial →

Sponsor

Sanofi — full company profile →

Who can join

Adults 2 to 5, any sex, with Rhinitis, Allergic, Perennial. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Double-blind phase: Change from baseline in mean daily instantaneous (immediately prior to dosing) Total Nasal Symptom Score (TNSS) over the 4-week double-blind period
Open-label phase: The efficacy variable is the global evaluation of efficacy as rated by the physician and the subject

Sponsor's own description

The purposes of this study are: * To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and * To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Triamcinolone

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06288685 — Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone · Phase 3 · completed
NCT06032039 — Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis. · EARLY_PHASE1 · unknown
NCT06004882 — Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for · NA · recruiting
NCT05992883 — NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis · Phase 3 · recruiting

Other Sanofi trials

Trials by the same sponsor.

NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00132925 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi
Last refreshed: 10 January 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00132925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing